Leukemia Research Reports最新文献_第3页

Selinexor combination with decitabine and half-dose CMG (Cytarabine+ Mitoxantrone+G-CSF) in Patients with refractory/relapsed acute myeloid leukemia (AML) previously exposed to Venetoclax: a single-center retrospective study Selinexor联合地西他滨和半剂量CMG（阿糖胞苷+米托蒽醌+G-CSF）治疗先前暴露于Venetoclax的难治性/复发性急性髓性白血病（AML）患者：一项单中心回顾性研究

IF 0.7

Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100523

Zi-Yu Zhao, Xiao-Lei Zhang, Ying Zhan, Ya-Bei Zuo, Jin-Ao Li, Jin-Hai Ren, Xiao-Ling Guo, Zi-Yuan Nie

引用次数: 0

Corrigendum to “First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report” [Leukemia Research Reports (2024) Volume 22, 100491] “用达拉单抗、来那度胺和地塞米松治疗POEMS综合征患者的一线治疗：一个病例报告”的勘误表[白血病研究报告（2024）卷22,100491]

IF 0.7

Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100499

E. Amabile, F. Fazio, M. Martelli, M.T. Petrucci

引用次数: 0

Case report: Experience of a rare case of primary acute mast cell leukemia 病例报告：一例罕见的原发性急性肥大细胞白血病

IF 0.7

Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100510

Zhijuan Pan, Ying Zhang, Yanru Guo, Jiajia Sun, Xinlei Guo, Zhiping Guo

{"title":"Case report: Experience of a rare case of primary acute mast cell leukemia","authors":"Zhijuan Pan, Ying Zhang, Yanru Guo, Jiajia Sun, Xinlei Guo, Zhiping Guo","doi":"10.1016/j.lrr.2025.100510","DOIUrl":"10.1016/j.lrr.2025.100510","url":null,"abstract":"<div><h3>Backgrounds</h3><div>Mast cell leukemia (MCL) is a rare and aggressive form of systemic mastocytosis with a poor prognosis. Understanding the different therapeutic responses to corticosteroids in MCL is crucial for improving patient outcomes.</div></div><div><h3>Case presentation</h3><div>We present a case of a 74-year-old Chinese female with primary acute MCL who exhibited different responses to dexamethasone and methylprednisolone. She was admitted with persistent fever, dyspnea, severe fatigue, and bone pain, alongside splenomegaly and cytopenia. Diagnosis was confirmed through marrow aspirate analysis, chemical staining, flow cytometry, and biopsy, revealing atypical mast cells positive for CD117, CD9, CD81, CD33, CD13, CD4, and partially for CD56, but negative for CD2 and CD25. Next-generation sequencing identified heterozygous mutations in <em>NRAS, DNMT3A</em>, and <em>TP5</em>3, with no <em>KIT</em> mutations. Initial treatment included corticosteroids and dasatinib. The patient showed a partial response to dexamethasone but significant improvement with methylprednisolone. Upon reintroduction of dexamethasone, symptoms recurred, which improved again after resuming methylprednisolone. The patient survived for three months post-diagnosis.</div></div><div><h3>Conclusion</h3><div>This case highlights the potential efficacy of methylprednisolone over dexamethasone in MCL treatment. This case underscores the importance of personalized treatment approaches in MCL, considering the distinct genetic profile and differential therapeutic responses to corticosteroids. Further research is needed to elucidate the mechanisms underlying these responses and to optimize treatment strategies for MCL.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100510"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143837824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-coding RNAs: Emerging contributors to chemoresistance in chronic myeloid leukemia 非编码rna：慢性髓性白血病化疗耐药的新贡献者

IF 0.7

Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100513

Laya Ghadyani nejhad , Mahsa Sohani , Nasrin Alizad Ghandforoush , Mohsen Nikbakht , Saeed Mohammadi , Mohammad Vaezi , Shahrbano Rostami , Bahram Chahardouli

{"title":"Non-coding RNAs: Emerging contributors to chemoresistance in chronic myeloid leukemia","authors":"Laya Ghadyani nejhad , Mahsa Sohani , Nasrin Alizad Ghandforoush , Mohsen Nikbakht , Saeed Mohammadi , Mohammad Vaezi , Shahrbano Rostami , Bahram Chahardouli","doi":"10.1016/j.lrr.2025.100513","DOIUrl":"10.1016/j.lrr.2025.100513","url":null,"abstract":"<div><div>Chronic myeloid leukemia (CML), is a myeloproliferative disease characterized by unregulated growth of blood forming cells in bone marrow and blood. The t(9;22)(q34;q11.2) translocation, which results in the formation of a hyperactive tyrosine kinase (<em>BCR-ABL</em>), is a hallmark of this disorder. Tyrosine kinase inhibitors such as imatinib has shown a great promise in reduction of CML cells. However, development of resistance to tyrosine kinase inhibitors has raised a great clinical concern about their future applications. Recently, non-coding RNAs, have shown to play significant regulatory roles in development of chemoresistance in CML cells. Discovering the underlying mechanisms of these non-coding RNAs might provide new opportunities for treating chemo-resistant forms of CML. These non-coding RNAs could be considered valuable therapeutic targets if they are found to play a role in the development of chemoresistance in CML cells. We mentioned the identified non-coding RNAs in development of chemoresistance in CML cells.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100513"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143947518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasm Tagraxofusp维持后造血干细胞移植为母细胞浆细胞样树突状细胞肿瘤患者提供了长期生存和可管理的安全性

IF 0.7

Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100518

Qaiser Bashir , Marina Konopleva , Glorette Abueg , Jeremy Ramdial , Chitra Hosing , Samer A. Srour , Amin Alousi , Uday R. Popat , Yago Nieto , Gheath Alatrash , Richard E. Champlin , Elizabeth J. Shpall , Muzaffar Qazilbash , Naveen Pemmaraju

{"title":"Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasm","authors":"Qaiser Bashir , Marina Konopleva , Glorette Abueg , Jeremy Ramdial , Chitra Hosing , Samer A. Srour , Amin Alousi , Uday R. Popat , Yago Nieto , Gheath Alatrash , Richard E. Champlin , Elizabeth J. Shpall , Muzaffar Qazilbash , Naveen Pemmaraju","doi":"10.1016/j.lrr.2025.100518","DOIUrl":"10.1016/j.lrr.2025.100518","url":null,"abstract":"<div><div>Presented here is the case of a 68-year-old woman with blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp (TAG) maintenance therapy post-allogeneic hematopoietic stem cell transplantation (allo-HCT). Prior to allo-HCT, the patient was treated with hydroxyurea and mini-CVD (cyclophosphamide, vincristine, and dexamethasone alternating with methotrexate (Methotrexate) and cytarabine) + venetoclax + TAG for 5 cycles, which induced morphologic complete remission with minimal residual disease. After allo-HCT, the patient had persistent cytogenic abnormalities 45,XX,der(7)add(7)(p13)del(7)(q11.2q22)add(7)(q32),add(12)(p13),-15,del(16)(q23),-17,+22,+2mar[1]/46,XX[19], and was then treated with TAG maintenance therapy at 9 mg/kg on a 28-day cycle for 16 cycles. At mid-treatment (cycle 6 of 16 cycles of TAG) and prior to TAG discontinuation (due to travel burden), the patient was negative for minimal residual disease and was in complete remission. There was no high-grade toxicity or capillary leak syndrome. The patient remains in complete remission as of present day (>17 months CR). This is the first case study illustrating the feasibility of long-term TAG maintenance post-allo-HCT to control BPDCN.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100518"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144306788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When the mask slips: A peripheral T-cell lymphoma disguised as lupus with myelofibrosis in a patient with May-Hegglin syndrome 当面具滑落梅-赫格林综合征患者伪装成狼疮伴骨髓纤维化的外周 T 细胞淋巴瘤。

IF 0.7

Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2024.100498

V Da Silva Constante , H Couvert , A Wolfromm , M Ilzkovitz

引用次数: 0

Impact of PD-1 and PD-L1 expression on treatment outcomes in newly diagnosed acute myeloid leukemia patients PD-1和PD-L1表达对新诊断急性髓性白血病患者治疗结果的影响

IF 0.7

Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100514

Ugur Calis , Merve Aydogan , Guldane Cengiz Seval , Klara Dalva , Selami Kocak Toprak

引用次数: 0

Involvement of the central nervous system in relapsed T-cell lymphoma: insights from four case studies 复发性t细胞淋巴瘤累及中枢神经系统：来自四个病例研究的见解

IF 0.7

Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100524

Radu Chiriac, Lucile Baseggio

引用次数: 0

Targeting menin for precision therapy in high-risk acute myeloid leukemia 以 Menin 为靶点，对高风险急性髓性白血病进行精准治疗。

IF 0.7

Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2024.100495

Abdur Jamil , Zaheer Qureshi , Zain Mary El-amir , Gillian Kupakuwana-Suk , Hamzah Akram , Mohsin Ahmad , Eric Huselton

引用次数: 0

Case report: Rechallenge with gilteritinib after acute pancreatitis in FLT3-positive AML 病例报告：flt3阳性AML患者急性胰腺炎后再用吉替尼治疗

IF 0.7

Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100503

Taner TAN , Genco Gençdal , Ümit Barbaros Üre , Olga Meltem AKAY

引用次数: 0